Days after announcing it was calling off further development of the CD47 inhibitor magrolimab in hematological cancers, Gilead Sciences, Inc. is hitting the brakes on clinical trials of the drug in solid tumors as well, at least for now. It’s only the latest hit to a multibillion-dollar effort to develop what had been seen as an immuno-oncology agent with potentially broad applicability in oncology.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?